StockData
ENvue Medical, Inc. logo

ENvue Medical, Inc. (FEED) stock

FEEDOTCOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026Score 5/30
$0.50+0.13 (+34.73%)

Close on Oct 19, 2026Market cap $3.08MP/E –Yield –

Earnings

ENvue Medical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2022
$272.00K
EPS, Q1 FY2022
-$0.04
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of ENvue Medical's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2022ended Mar 31, 2022May 17, 2022before the open$272.00K–-$0.04Release
Q2 FY2021ended Jun 30, 2021Aug 17, 2021before the open–––Filing
Q3 FY2020ended Sep 30, 2020Nov 17, 2020after the close–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

ENvue Medical has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When ENvue Medical puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases ENvue Medical filed with the SEC as exhibits to Form 8-K or 6-K

  1. Medical, Inc. Announces 1-for-12 Reverse Stock Split
    News
  2. Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and ‘FEED’
    Update
  3. Feeding Tube Placement System Identified as Core Growth Platform
    Update
  4. Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    News
  5. NanoVibronix Announces Reverse Stock Split
    News
  6. TEXAS – June 4, 2025 – NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a
    News
  7. Announces Pricing of $10 Million Public Offering of Preferred Stock and Warrants
    News
  8. Independent Study of the NanoVibronix UroShield ® Device Published in the Australian and New Zealand Continence Journal
    Update
  9. Stock Will Begin Trading on Split-Adjusted Basis on March 14, 2025
    News
  10. MEDICAL HOLDINGS, CORP. (FORMERLY ENVIZION HOLDINGS CORP.)
    Update
  11. Interim Consolidated Statements of Operations
    Update
  12. PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
    Update
  13. Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan
    Update
  14. 8-K exhibit EX-99.1
    Update
  15. Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of
    News

See a number that looks wrong?